Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ipca LaboratoriesNSE:IPCALAB -0.63%86 EV-to-EBIT is 27.46 as of Aug. 02, 2026, which is 9% above its 10-year median of 25.22. GuruFocus rates NSE:IPCALAB with a GF Score™ of 86/100 and a GF Value™ of ₹1,603.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 691 Drug Manufacturers companies, Ipca Laboratories ranks worse than 71.78% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Ipca Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹416,965 Mil.
Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,485 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories EV-to-EBIT Related Terms
Ipca Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Ipca Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ipca Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Ipca Laboratories's EV-to-EBIT falls into.
Ipca Laboratories's current Enterprise Value is ₹452,687 Mil.
Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16,485 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ipca Laboratories (NSE:IPCALAB) has a EV-to-EBIT of 27.46 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ipca Laboratories and its competitors. This is near median its historical median of 25.22. Over the past decade, Ipca Laboratories' EV-to-EBIT has ranged from 14.84 to 115.34. According to the industry distribution chart, Ipca Laboratories ranks #496 out of 691 companies in the Drug Manufacturers industry, placing it in the top 71.8%.
Is Ipca Laboratories' EV-to-EBIT too high?
Ipca Laboratories' current EV-to-EBIT of 27.46 is near median its 10-year median of 25.22. Over the past 10 years, this metric has ranged from a low of 14.84 to a high of 115.34. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Ipca Laboratories' value of 27.46 is 75% above this industry median. Based on the distribution chart, Ipca Laboratories ranks #496 out of 691 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ipca Laboratories has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ipca Laboratories ranks #496 out of 691 companies for EV-to-EBIT. This places Ipca Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.69. Ipca Laboratories' value of 27.46 is 75% above this benchmark. Historically, Ipca Laboratories' own EV-to-EBIT has ranged from 14.84 to 115.34 over the past decade. While the company's 10-year median is 25.22 vs. the industry median of 15.69, Ipca Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipca Laboratories's current EV-to-EBIT of 27.46 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Ipca Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipca Laboratories's current EV-to-EBIT is 27.46, which is near median its own 10-year median of 25.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,603.34, compared to a current price of ₹1,747.80 — trading 9% above its estimated fair value. The current EV-to-EBIT is 27.46, which is near median its 10-year median of 25.22 and 75% above the Drug Manufacturers industry median of 15.69. Ipca Laboratories' overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current EV-to-EBIT is 27.46 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued.
The current stock price of ₹1,747.80 is trading 9% above its estimated GF Value™ of ₹1,603.34.
GuruFocus considers Ipca Laboratories to be Fairly Valued.
Key valuation signals for NSE:IPCALAB:
EV-to-EBIT: 27.46 (near median its 10-year median of 25.22)
GF Value™: ₹1,603.34 vs. price of ₹1,747.80 (9% above fair value)
Industry Position: 75% above the Drug Manufacturers median (#496 of 691)
No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
86GF Score
Get the complete analysis for NSE:IPCALAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IPCALAB has been successfully added to your 
